NCT03705845Active, not recruitingPhase 1/2
Tocotrienols for Obesity of Postmenopausal Women
Actions of Dietary Tocotrienols on Obesity
Source: ClinicalTrials.gov · Last updated 2 Oct 2026
Brief summary (registry, in English)
Postmenopausal women are at a risk of excessive weight gain, bone loss, hypertension, and metabolic syndrome. Obesity-induced chronic low-grade inflammation is initiated by excess nutrients in metabolic cells. Recent studies have indicated tocotrienols (one kind of vitamin E, a potent antioxidant) supplement may be good for mitigating negative impacts of obesity in postmenopausal women. The purpose of the study is to examine the effect of 24-week tocotrienols on obesity-associated outcome measurements in postmenopausal women. The investigators will enroll 60 qualified women at the start of the study and randomly assigned to no tocotrienols (placebo) or tocotrienols group for 24 weeks. Obesity-associated measurements will be recorded using blood, urine, adipose tissue, and fecal samples. All data will be analyzed statistically.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 10 Oct 2018
- Start date
- 15 Mar 2019
- Primary completion date
- 30 Dec 2024
- Lead sponsor
- Texas Tech University Health Sciences Center
- Diseases
- Obesity
- NCT number
- NCT03705845
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 60
- From 15 Mar 2019 to the primary completion date, 30 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Unstable body weight (more than 5% change in body weight) within 3 months before intervention begins.
- Changes to medications or supplements (i.e., steroids, statins) within 3 months of the baseline study visit that could affect lipid metabolism. • If they change any medications/supplements after the baseline visit that will affect lipid metabolism, their study participation will end.
Other illness
- Serious chronic disease (e.g., unstable cardiovascular disease, uncontrolled diabetes and hypertension, and active cancer).
Other
- Taking anticoagulants that may interact with TT.
Who the study is looking for
- PMW with BMI ≥30 kg/m2.
- Normal liver, kidney, and thyroid function (TSH)-sent to Quest Diagnostic Laboratory.
- Sedentary using International Physical Activity Questionnaire (IPAQ-short form).
Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Texas Tech University Health Sciences Center Coordinator of this site? Confirm its status | Lubbock | United States | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.